These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180 [TBL] [Abstract][Full Text] [Related]
7. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Price SJ; Fryer TD; Cleij MC; Dean AF; Joseph J; Salvador R; Wang DD; Hutchinson PJ; Clark JC; Burnet NG; Pickard JD; Aigbirhio FI; Gillard JH Clin Radiol; 2009 Jan; 64(1):52-63. PubMed ID: 19070698 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963 [TBL] [Abstract][Full Text] [Related]
9. Repeatability of Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473 [TBL] [Abstract][Full Text] [Related]
10. (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. Zhao F; Li M; Wang Z; Fu Z; Cui Y; Chen Z; Yu J PLoS One; 2015; 10(3):e0118769. PubMed ID: 25738617 [TBL] [Abstract][Full Text] [Related]
11. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Jeong SY; Lim SM Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845 [TBL] [Abstract][Full Text] [Related]
18. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma. Yamane T; Takaoka A; Kita M; Imai Y; Senda M Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262 [TBL] [Abstract][Full Text] [Related]
19. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030 [TBL] [Abstract][Full Text] [Related]